What is the evidence?

People have been studied and the studies disagree. That usually means any real effect is small enough to be swamped by trial design and chance.

Contradictory is its own answer, and not an encouraging one.

Studied in people, never approved. Sometimes the effect was too small, sometimes safety concerns emerged. Either way the programme that would have set a safe dose was not finished.

Ask what the trials found besides the headline effect.

Some human work exists but it is small and was never carried through to licensing.

Early human data is a reason to run trials, not a reason to act.

Decades of real prescribing in one regulatory system, without the controlled trial data Western regulators require. Long use tells you it has not obviously harmed people; it does not establish effect size.

A real critique of Western trial bias exists here. It also does not create missing data.

The positive findings come almost entirely from the group that developed the compound. Independent replication is how science catches error and enthusiasm.

Ask whether anyone else has found the same thing.

Tested in people for the purpose it is sold for, and it failed. This is not missing evidence. It is evidence pointing the other way.

The strongest possible reason not to bother.

Effects reported in rats, mice or cells in a dish, with essentially nothing in people. Most compounds that work in animals fail in humans.

Look for the word rat, mouse or in vitro in any source.

Animal and laboratory work only. No human trial evidence at all.

Nobody can honestly quote you a benefit or a risk figure.

No human clinical studies exist. In several July 2026 FDA reviews, this was the regulator's own finding.

An absence of evidence is not evidence of suppression.

No human studies of this compound. Where controlled human data exists, it used a different, modified molecule, and research on that gets presented as research on this.

Check which molecule a study actually used.

A real drug candidate that entered human trials and was dropped before finishing. The work that would have established safety and a dose was never completed.

Abandonment is not proof of danger, and not proof of suppression either.

Early pharmacology may show it does something measurable, such as moving a blood marker. Whether that produces the outcomes it is sold for has not been tested.

Moving a marker is not the same as a benefit.

A proper clinical programme found a specific harm and stopped. This is the strongest negative evidence in the register: not an absence of data, but data that came back bad enough to end the trial.

A halted trial is a finding. Treat it as one.

Genuine randomised trials in humans, and no regulator has approved it. Usually because results were mixed, which in small rare-disease trials can mean a modest real effect or none at all.

Check which condition the trials were in, and whether it resembles yours.

Small early human work confirming the compound does something measurable, with no completed programme and no approval.

Measurable is not the same as beneficial.

It was trialled, approved and sold, and then the product was discontinued. The historical safety file exists; a current one, a marketed product and active pharmacovigilance do not.

Find out why it was withdrawn before assuming it was commercial.

The underlying biology is well established and the specific modified molecule being sold has never been tested in humans. Strong enough to do something, with nobody having established what.

Check whether a study used the licensed molecule or the modified one on sale.